PL3261645T3 - Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów - Google Patents

Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów

Info

Publication number
PL3261645T3
PL3261645T3 PL16756426T PL16756426T PL3261645T3 PL 3261645 T3 PL3261645 T3 PL 3261645T3 PL 16756426 T PL16756426 T PL 16756426T PL 16756426 T PL16756426 T PL 16756426T PL 3261645 T3 PL3261645 T3 PL 3261645T3
Authority
PL
Poland
Prior art keywords
anorexia
appetite
cats
dogs
stimulation
Prior art date
Application number
PL16756426T
Other languages
English (en)
Inventor
William BUHLES
Richard CORTEZ
Kristin MAAS
Geeta Srivastava
Daniel Perez
Original Assignee
Dechra Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dechra Limited filed Critical Dechra Limited
Publication of PL3261645T3 publication Critical patent/PL3261645T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Finger-Pressure Massage (AREA)
PL16756426T 2015-02-27 2016-02-26 Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów PL3261645T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126188P 2015-02-27 2015-02-27
PCT/US2016/019730 WO2016138357A1 (en) 2015-02-27 2016-02-26 Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
EP16756426.9A EP3261645B1 (en) 2015-02-27 2016-02-26 Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats

Publications (1)

Publication Number Publication Date
PL3261645T3 true PL3261645T3 (pl) 2021-12-06

Family

ID=56789326

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16756426T PL3261645T3 (pl) 2015-02-27 2016-02-26 Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów

Country Status (14)

Country Link
US (1) US10603272B2 (pl)
EP (1) EP3261645B1 (pl)
JP (1) JP6876003B2 (pl)
AU (1) AU2016222550B2 (pl)
CA (1) CA3013771C (pl)
DK (1) DK3261645T3 (pl)
ES (1) ES2874549T3 (pl)
HR (1) HRP20211040T1 (pl)
HU (1) HUE055000T2 (pl)
PL (1) PL3261645T3 (pl)
PT (1) PT3261645T (pl)
RS (1) RS62055B1 (pl)
SI (1) SI3261645T1 (pl)
WO (1) WO2016138357A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US10463854B2 (en) 2015-02-24 2019-11-05 Elira, Inc. Systems and methods for managing symptoms associated with dysmenorrhea using an electro-dermal patch
WO2018081423A1 (en) * 2016-10-26 2018-05-03 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US12251455B2 (en) 2019-03-19 2025-03-18 Cargill, Incorporated High oil content topical personal care products
CN112107584A (zh) * 2020-07-17 2020-12-22 上海信元动物药品有限公司 治疗宠物恶心呕吐、食欲减退的米氮平制剂组成及其工艺

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE99943T1 (de) 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
EP0813873B1 (en) 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP1829539A3 (en) 1996-11-05 2008-02-20 HEADEXPLORER ApS A method for treating tension-type headache
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
ATE289816T1 (de) 1997-11-14 2005-03-15 Akzo Nobel Nv Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ES2267253T3 (es) 1998-02-27 2007-03-01 The Board Of Trustees Of The University Of Illinois Agentes con actividad relacionada con la serotonina para el tratamiento de la apnea del sueño.
WO1999051237A1 (en) 1998-04-02 1999-10-14 Akzo Nobel N.V. Oral liquid antidepressant solution
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
PL351395A1 (en) 1999-04-19 2003-04-07 Teva Pharma Novel synthesis of piperazine ring
AU781221B2 (en) 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
CN1355698A (zh) 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
TWI256309B (en) 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
AU6019900A (en) 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
WO2001042239A1 (en) 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
CA2396209C (en) 2000-02-11 2009-09-01 Akzo Nobel N.V. The use of mirtazapine for the treatment of sleep disorders
US7678387B2 (en) 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20020072602A1 (en) 2000-07-07 2002-06-13 Claude Singer Micronized mirtazapine
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
US20040106124A1 (en) 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
CA2438446A1 (en) 2001-03-01 2002-02-14 Teva Pharmaceutical Industries Ltd. Methods for the preparation of mirtazapine intermediates
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
ITMI20011446A1 (it) 2001-07-06 2003-01-06 Altergon Sa Composizioni farmaceutiche di principi attivi suscettibili di somministrazione illecita
WO2007064311A1 (en) 2001-07-10 2007-06-07 Teva Pharmaceutical Industries Ltd. Micronized mirtazapine
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
EP1941878A1 (en) 2002-01-10 2008-07-09 Biovail Laboratories International Srl Sedative non-benzodiazepine formulations
AU2003213787A1 (en) 2002-03-06 2003-09-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20030194420A1 (en) 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
FR2842734A1 (fr) 2002-07-24 2004-01-30 Ethypharm Sa Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale et compositions pharmaceutiques a administration orale
US20120156144A1 (en) 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
ES2411961T5 (es) 2002-11-01 2017-04-27 Rutgers, The State University Of New Jersey Vehículos de suministro en forma de geoda
US20050013845A1 (en) 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US7041826B2 (en) 2003-06-02 2006-05-09 Aurobindo Pharma Ltd. Process for preparing 1-methyl-3-phenylpiperazine using a novel intermediate
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
AU2003903597A0 (en) 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
AU2004264974A1 (en) 2003-08-15 2005-02-24 Arius Two, Inc. Adhesive bioerodible transmucosal drug delivery system
WO2005034921A1 (en) 2003-10-07 2005-04-21 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
WO2005051349A2 (en) 2003-11-25 2005-06-09 Aurobindo Pharma Ltd. Pharmaceutical compositions of mirtazapine
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005089511A2 (en) 2004-03-19 2005-09-29 Transform Pharmaceuticals, Inc. Novel pharmaceutical forms, and methods of making and using the same
TW200538100A (en) 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
DE102004034043A1 (de) 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
ES2246161B1 (es) 2004-07-22 2007-04-01 Medichem, S.A. Proceso mejorado para la fabricacion de mirtazapina.
EP1776121A2 (en) 2004-08-13 2007-04-25 Omeros Corporation Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
TW200631584A (en) 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
WO2006088305A1 (en) 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
WO2006118212A1 (ja) 2005-04-27 2006-11-09 Umn Pharma Inc. 膵炎の予防および治療剤
US20090306046A1 (en) 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
CA2613875C (en) 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
WO2007012154A1 (en) 2005-07-27 2007-02-01 Carlos Henrique Horta Lima Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties.
WO2007019880A1 (en) 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007035003A1 (ja) 2005-09-26 2007-03-29 Sumitomo Chemical Company, Limited 光学活性なピペラジン化合物の製造方法
US20070092586A1 (en) 2005-10-26 2007-04-26 Alamo Pharmaceuticals Compositions and methods for the administration psychotropic drugs which modulate body weight
EP1948248A2 (en) 2005-11-06 2008-07-30 Katz-Brull, Rachel Magnetic resonance imaging and spectroscopy means and methods thereof
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
US7541371B2 (en) 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease
CA2644985A1 (en) 2006-03-06 2007-09-13 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
FR2900339B1 (fr) 2006-04-28 2008-07-25 Univ Claude Bernard Lyon I Eta Utilisation d'un compose qui induit une augmentation du taux de serotonine libre dans l'organisme, pour la preparation d'un medicament destine a traiter des degenerescences du muscle squelettique
TW200808804A (en) 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
US20070270413A1 (en) 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
DE102006027792A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20080014252A1 (en) 2006-07-14 2008-01-17 Delprete Keith Topical compositions with long lasting effect
WO2008060397A2 (en) 2006-11-03 2008-05-22 Noven Therapeutics, Llc Method of treating thermoregulatory disfunction
MX2009005446A (es) 2006-11-22 2009-06-02 Organon Nv Sistema de suministro vaginal para mirtazapina.
WO2008104996A2 (en) 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
JP5192707B2 (ja) 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
JP5635395B2 (ja) 2007-04-11 2014-12-03 メルク・シャープ・エンド・ドーム・ベー・フェー 鏡像異性的に純粋なベンゾアゼピンの調製方法
CN101679431B (zh) 2007-04-11 2013-08-14 Msd欧斯股份有限公司 制备四环苯并氮杂卓的对映异构体的方法
US7994314B2 (en) 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
US20080255348A1 (en) 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
WO2009018088A2 (en) 2007-08-01 2009-02-05 Link Medicine Corporation Imaging of alpha-synuclein
WO2009055001A2 (en) 2007-10-23 2009-04-30 Fred Hutchinson Cancer Research Center Methods of treating aging and methods of screening candidate agents therefor
ES2494853T3 (es) * 2007-11-02 2014-09-16 Acrux Dds Pty Ltd Sistema de administración transdérmica
MX2010009493A (es) 2008-02-28 2010-12-20 Rp Scherer Technologies Llc Proceso para minimizar el polimorfismo.
US20110201804A1 (en) 2008-10-22 2011-08-18 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
EP2385944A4 (en) 2009-01-09 2013-06-19 Harvard College FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF
WO2010148519A1 (en) 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
WO2011091050A1 (en) 2010-01-19 2011-07-28 Nektar Therapeutics Oligomer-tricyclic conjugates
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
WO2012026963A2 (en) 2010-08-23 2012-03-01 Darren Rubin Systems and methods of aerosol delivery with airflow regulation
DE102010049706A1 (de) 2010-10-28 2012-05-03 Hexal Ag Herstellung orodispersibler Filme
JP5073124B2 (ja) 2010-12-07 2012-11-14 祐徳薬品工業株式会社 ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
GB2503187A (en) 2011-09-15 2013-12-25 Univ Sussex Composition for use in the treatment of neurodevelopmental disorders
US20130274247A1 (en) * 2012-04-17 2013-10-17 Jessica Quimby Mirtazapine as an Appetite Stimulant for Cats
JPWO2013183407A1 (ja) * 2012-06-05 2016-01-28 祐徳薬品工業株式会社 ミルタザピン含有経皮吸収型貼付製剤
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US20140271727A1 (en) 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
EP2856934A1 (en) 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
GB201320675D0 (en) 2013-11-22 2014-01-08 Univ Nottingham Composition
IL305990B2 (en) 2013-12-03 2025-12-01 Intra Cellular Therapies Inc Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
FR3015289B1 (fr) 2013-12-20 2017-01-13 Virbac Mirtazapine injectable

Also Published As

Publication number Publication date
DK3261645T3 (da) 2021-06-07
AU2016222550A1 (en) 2017-08-31
EP3261645B1 (en) 2021-04-28
US20180021251A1 (en) 2018-01-25
HUE055000T2 (hu) 2021-10-28
AU2016222550B2 (en) 2020-07-16
HRP20211040T1 (hr) 2021-10-01
CA3013771A1 (en) 2016-09-01
EP3261645A4 (en) 2018-08-08
EP3261645A1 (en) 2018-01-03
SI3261645T1 (sl) 2021-08-31
RS62055B1 (sr) 2021-07-30
ES2874549T3 (es) 2021-11-05
US10603272B2 (en) 2020-03-31
JP6876003B2 (ja) 2021-05-26
PT3261645T (pt) 2021-06-17
JP2018507911A (ja) 2018-03-22
CA3013771C (en) 2024-01-02
WO2016138357A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
SI3261645T1 (sl) Stimulacija apetita, uravnavanje izgube mase in zdravljenje anoreksije pri psih in mačkah
IL267319A (en) Management of a grant
ZA201606158B (en) Treatment of metabolic disorders in equine animals
PL3086657T3 (pl) Suplement paszowy dla zwierząt i sposób
GB201418007D0 (en) Animal skin substrate Treatment apparatus and method
GB201418006D0 (en) Animal skin substrate treatment apparatus and method
PL3096765T3 (pl) Leczenie zaburzeń metabolicznych u zwierząt psowatych
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
GB201700661D0 (en) Power harvesting apparatus and design metho
PL3307058T3 (pl) Zwijana smycz dla zwierząt i sposób jej obsługi
GB201519200D0 (en) Skin care composition and method thereof
GB201508219D0 (en) Skin and muscle stimulation apparatus
PL3367995T3 (pl) Kompozycja do pielęgnacji skóry oraz jej sposób
ZA201703052B (en) Animal model for dry eye and methods of use of such animals
GB201419207D0 (en) Animal halter
GB201721598D0 (en) Animal weight management
IL234889A0 (en) Wastewater treatment from livestock farming
PL3128838T3 (pl) Stymulatory roślin, ich zastosowanie i sposób stymulacji roślin
KR101758124B9 (ko) 축산 분뇨 처리시스템
PL3139764T3 (pl) Sposób wytwarzania paszy dla zwierząt i jej zastosowanie
HUE048864T2 (hu) Lizobaktin szarvasmarhafélék tõgygyulladásának kezelésében történõ alkalmazásra
GB201513872D0 (en) Agent for use in treating fish parasites
AU2014904293A0 (en) Treated Animal Litter and Bedding
SG10201401461SA (en) Livestock treatment method and apparatus
ZA201402610B (en) Livestock treatment method and apparatus